buparlisib
buparlisib: 3 clinical trials tracked.
buparlisib evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
What is verified about buparlisib, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (3)
An Open-Label, Multicenter, Phase 1a Study of AN2025 and AN0025 in Double Combination With Atezolizumab and in Triple Combination With Atezolizumab in Patients With Advanced Solid Tumors
Primary endpoint: Primary Outcome Measure - Dose Limiting Toxicities (DLTs)
A Phase Ib, Open-label, Multi-center, Two-arm, Dose-finding Study to Assess Safety and Efficacy of the Oral Combination or INC424 (INC424) and BKM120 in Patients With Primary Myelofibrosis (PMF), Postpolycythemia Vera-myelofibrosis (PPV-MF), or Post-essential Thrombocythemia-myelofibrosis (PET-MF)
Primary endpoint: Incidence of dose limiting toxicities
A Phase II Study of BKM 120 for Patients With Recurrent Glioblastoma and Activated PI3K Pathway
Primary endpoint: Change in pAKT (S473) Immunohistochemistry (IHC) Score From Baseline to Surgery [Cohort 1]